Core Viewpoint - A class action securities lawsuit has been filed against Flywire Corporation, alleging securities fraud that affected investors between February 28, 2024, and February 25, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Flywire's revenue growth was overstated, and the negative impact of permit and visa-related restrictions on its business was understated [2]. - Defendants' public statements regarding Flywire were allegedly materially false and misleading throughout the relevant period [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 23, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

https://securitiesclasslaw.com/securities/3d-systems-corporation-loss-submission-form/?id=160422&from=4 CLASS PERIOD: August 13, 2024 to May 12, 2025 NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of 3D Systems Corporation (NYSE: DDD). Shareholders who purchased shares of DDD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any re ...

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited regarding potential securities fraud or unlawful business practices [1] - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission related to disclosures about its prostate cancer therapeutic candidates, leading to a significant drop in its ADR price [3] Group 1 - The investigation by Pomerantz LLP focuses on whether Telix and its officers or directors have engaged in unlawful business practices [1] - Following the SEC subpoena, Telix's ADR price fell by $1.70, or 10.44%, closing at $14.58 on July 23, 2025 [3]

Core Viewpoint - Molina Healthcare, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results and guidance revisions [1][4]. Financial Performance - On July 7, 2025, Molina reported preliminary adjusted earnings of approximately $5.50 per share and lowered its full-year 2025 adjusted earnings guidance by over 10% to a range of $21.50 to $22.50 per share [3]. - Following this announcement, Molina's stock price decreased by $6.97, or about 2.9%, closing at $232.61 per share [3]. - On July 23, 2025, Molina released finalized second-quarter results, reporting adjusted earnings per diluted share of $5.48, which missed both analyst estimates and prior guidance [4]. - The earnings shortfall was attributed to increased medical cost pressures, including higher utilization of behavioral health, pharmacy, and inpatient/outpatient services [4]. - Molina again revised its full-year guidance downward due to updated information and revised assumptions regarding medical cost trends [4]. - Following the finalized results, Molina's stock price fell by $32.03, or approximately 16.8%, closing at $158.22 per share [5].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Confluent, Inc. and its officers or directors, following a significant drop in the company's stock price after disappointing financial results [1][3]. Financial Performance - On July 30, 2025, Confluent announced its financial results for Q2 2025, indicating that consumption growth was negatively affected by ongoing optimization, with month-over-month trends lagging behind previous years [3]. - The company's stock price fell by $8.68, or 32.86%, closing at $17.73 per share on July 31, 2025, following the earnings call [3]. Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Confluent, suggesting that there may be grounds for a class action lawsuit due to the alleged securities fraud [1].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Lineage, Inc. and its officers or directors [1] Group 1: Company Overview - Lineage, Inc. conducted its initial public offering on July 25, 2024, offering 56,882,051 shares at a price of $78.00 per share [3] - The company reported a total revenue of $1.29 billion for Q1 2025, reflecting a decrease of 2.7% compared to previous periods, attributed to more normal seasonal trends after elevated inventory levels [3] Group 2: Stock Performance - Following the Q1 2025 financial results announcement, Lineage's stock price dropped by $8.26 per share, or 14.62%, closing at $48.23 per share on April 30, 2025 [3]

Core Viewpoint - A class action lawsuit has been filed against Lockheed Martin Corporation, alleging securities fraud and unlawful business practices related to significant financial losses in various business segments [2][4]. Financial Performance - On October 22, 2024, Lockheed announced a recognition of losses amounting to $80 million in its Aeronautics segment due to higher-than-anticipated costs, leading to a stock price drop of 6.12% [4][6]. - On January 28, 2025, the company reported pre-tax losses of $1.7 billion linked to classified programs, resulting in a net earnings decline from $6.9 billion ($27.55 per share) in 2023 to $5.3 billion ($22.31 per share) in 2024 [5]. - In the second quarter of 2025, Lockheed disclosed $1.6 billion in program losses, including $950 million from its Aeronautics Classified program and additional losses from other projects, causing a stock price decline of 10.8% [7][8]. Legal Proceedings - Investors who purchased Lockheed securities during the class period have until September 26, 2025, to request appointment as Lead Plaintiff in the class action lawsuit [2].

Core Viewpoint - A class action securities lawsuit has been filed against Fiserv, Inc. alleging securities fraud that negatively impacted investors between July 24, 2024, and July 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Fiserv made false statements regarding its Clover platform, which was forced upon Payeezy merchants due to issues with the older platform [2]. - It is alleged that the revenue growth of Clover was artificially inflated by the forced conversions, masking a slowdown in acquiring new merchants [2]. - Following the conversions, many former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and poor customer service, leading to a significant slowdown in Clover's growth [2]. - The lawsuit asserts that Fiserv's positive statements about Clover's growth strategies and business prospects were materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until September 22, 2025, to request to be appointed as lead plaintiff in the case [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

Core Viewpoint - Fiserv, Inc. is facing a class action lawsuit due to significant declines in its stock price following disappointing growth figures for its Clover payment gateway, which has raised concerns about the company's business practices and transparency [1][5]. Group 1: Financial Performance - On April 24, 2025, Fiserv reported a gross payment volume (GPV) growth of only 8% for Clover in Q1 2025, a decline from the previous year's growth of 14% to 17% [2]. - Following this announcement, Fiserv's stock price dropped by $40.20, or 18.5%, closing at $176.90 per share [3]. - On May 15, 2025, Fiserv indicated that GPV growth deceleration would persist throughout 2025, leading to a further stock price decline of $30.73, or 16.2%, to $159.13 per share [3]. - On July 23, 2025, Fiserv lowered its full-year organic growth guidance and reported a deceleration in quarterly organic revenue in the Merchant segment to 9% year-over-year from 11%, resulting in a stock price drop of $22.98, or 13.8%, to $143.00 per share [4]. Group 2: Lawsuit Details - The class action lawsuit alleges that Fiserv made materially false and misleading statements and failed to disclose adverse facts about its business operations and prospects during the class period [5]. - Specific allegations include that Fiserv forced Payeezy merchants to migrate to Clover due to cost issues, which temporarily inflated Clover's revenue growth and concealed a slowdown in new merchant business [5]. - The lawsuit claims that many former Payeezy merchants switched to competitors due to Clover's high pricing and inadequate customer service, leading to a significant slowdown in Clover's GPV growth [5].

Core Viewpoint - The complaint against Fiserv alleges violations of federal securities laws due to misleading statements regarding the performance and growth of its Clover platform, particularly following the forced migration of Payeezy merchants [2]. Group 1: Allegations Against Fiserv - Fiserv allegedly forced Payeezy merchants to migrate to its Clover platform due to issues with the older Payeezy platform [2]. - The revenue growth and gross payment volume (GPV) of Clover were temporarily inflated by these forced conversions, masking a slowdown in new merchant business [2]. - A significant number of former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and compatibility issues, leading to a slowdown in Clover's GPV growth [2]. Group 2: Market Reaction and Stock Performance - On April 24, 2025, Fiserv reported Clover GPV growth of only 8% for Q1 2025, a decline from 14-17% in 2024, resulting in an 18.5% drop in stock price to $176.90 [3]. - On May 15, 2025, Fiserv disclosed that GPV growth deceleration would persist throughout 2025, causing a further 16.2% decline in stock price to $159.13 [3]. - On July 23, 2025, Fiserv lowered its full-year organic growth guidance and reported a deceleration in quarterly organic revenue growth to 9% year-over-year, leading to a 13.9% drop in stock price to $143.00 [3].